Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporfin VTP in LG UTUCwith topline data expected in 2026 –– ...

Researchers from the Paris Brain Institute and Sainte-Justine University Hospital in Montreal have, for the first time, ...

Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.

DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial ...

Scientists have made a major advance in developmental neuroscience, creating the very first detailed atlas of how the vascular network of a mouse's brain grows after birth. Their study is published in ...

AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...

Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a ...

Purpose: Clinical evaluation of novel agents that target tumor blood vessels requires pharmacodynamic end points that measure vascular damage. Positron emission tomography (PET) was used to measure ...